Core Viewpoint - The inclusion of Lairosilib (GB491) in the National Medical Insurance Drug List is expected to enhance patient accessibility and accelerate commercialization, thereby boosting innovative returns for the company [1]. Group 1: Drug Inclusion - Lairosilib (GB491) has been included in the National Medical Insurance Drug List published by the National Healthcare Security Administration, effective from January 1, 2026 [1]. - This marks the first time Lairosilib (GB491) has been included in the national medical insurance drug list [1]. Group 2: Drug Description and Indications - Lairosilib (GB491) is a novel, highly selective oral CDK4/6 inhibitor, indicated for adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer [1]. - It is used in combination with aromatase inhibitors as initial endocrine therapy and with Fulvestrant for patients with disease progression after prior endocrine therapy [1]. Group 3: Impact on Patients and Market - The inclusion in the insurance list is expected to significantly improve drug accessibility for patients and reduce their financial burden [1]. - This development is anticipated to accelerate the commercialization process and market penetration of Lairosilib (GB491) [1].
嘉和生物-B(06998)：来罗西利(GB491)纳入国家医保药品目录